<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454271</url>
  </required_header>
  <id_info>
    <org_study_id>CERAVERBIO11</org_study_id>
    <secondary_id>2011-A00597-34</secondary_id>
    <nct_id>NCT01454271</nct_id>
  </id_info>
  <brief_title>Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate</brief_title>
  <official_title>Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire Ceraver-Osteal</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire Ceraver-Osteal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of infection after primary Total Hip Arthroplasties (THA)is generally estimated to
      be less than 1% but remains a severe and costly complication, source of morbidity and even
      mortality. The &quot;biofilm&quot; forms very early after the bacterial contamination of the prosthesis
      and poses a number of clinical challenges due to his resistance to immune defence mechanisms
      and antibiotics. Preventive strategies are needed. The poly sodium styrene sulfonate (pNaSS)
      is a bioactive polymer. In vitro and in vivo studies showed that poly sodium styrene
      sulfonate grafted on titane surfaces reduce significantly the bacterial adhesion. They also
      proved his biocompatibility and osseous-integration.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Femoral component osseous-integration</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Scoring system of Engh</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Infection (yes/no) :
Clinical, biological or radiological THA infection signs. In the case of infection suspicion, hip aspiration will be performed with joint fluid culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>One, three, six and twelve months after surgery</time_frame>
    <description>SF-36 score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hip Arthroplasty Replacement</condition>
  <arm_group>
    <arm_group_label>Total Hip Arthroplasty CERAFIT® grafted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Hip Arthroplasty Replacement</intervention_name>
    <description>Total Hip Arthroplasty Replacement</description>
    <arm_group_label>Total Hip Arthroplasty CERAFIT® grafted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age less than 75 years old

          -  Aetiologies for THA : primary osteoarthritis, inflammatory diseases,Osteonecrosis

        Exclusion Criteria:

          -  Previous infectious hip arthritis

          -  Previous surgeries on the operated hip

          -  Revision of THA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Hardy, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ambroise Paré Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahnaz Klouche, MD</last_name>
    <phone>+33 (0) 6 28 35 04 78</phone>
    <email>klouche_shahnaz@yahoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ambroise Paré Hospital. Orthopaedic surgery department</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <state>Ile de France</state>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philippe Hardy, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Bauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit Rousselin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Hip arthroplasty</keyword>
  <keyword>Hip Osteoarthritis</keyword>
  <keyword>Infection after Total Hip Arthroplasty</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

